Key statistics
On Friday, Acrivon Therapeutics Inc (ACRV:NMQ) closed at 7.47, 134.17% above the 52 week low of 3.19 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.50 |
---|---|
High | 7.71 |
Low | 7.33 |
Bid | 7.40 |
Offer | 11.95 |
Previous close | 7.59 |
Average volume | 217.07k |
---|---|
Shares outstanding | 30.97m |
Free float | 18.68m |
P/E (TTM) | -- |
Market cap | 231.36m USD |
EPS (TTM) | -2.77 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
- Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
- Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
- Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Acrivon Therapeutics Announces $130 Million Private Placement Financing
More ▼